annual meeting program - American Society of Clinical Oncology

MONDAY
Monday, June 7, 2010
Brd. 2F Clinical relevance of germ cell cancer cells detected by real time PCR in
apheresis products of poor risk patients undergoing high dose
chemotherapy. (Abstract #4579)
A. Burchert, L. Sytik, A. Lorch, J. T. Hartmann, C. Bokemeyer, O. Rick, J. Beyer,
T. D. Kim, A. Neubauer
Brd. 2G Management of testicular neoplasms in France and compliance with national
guidelines. (Abstract #4580)
S. Culine, S. Hoppe, C. Hennequin, M. Saves, N. Mottet, FRANCIM network
Brd. 2H 2- 18 fluoro-deoxy-d-glucose positron emission tomography (FDG-PET) for
postchemotherapy seminoma residuals: A retrospective validation of the
SEMPET trial. (Abstract #4581)
M. Bachner, P. Zucali, A. Horwich, K. Oechsle, Y. Loriot, A. Flechon,
C. K. Kollmannsberger, J. R. Germa-Lluch, J. Oldenburg, M. De Santis
Brd. 3A Sunitinib in patients with multiply relapsed or cisplatin-refractory germ cell
cancer: A CUOG/GTCSG cooperative phase II study. (Abstract #4582)
C. K. Kollmannsberger, K. Oechsle, T. Cheng, F. Mayer, P. Czaykowski,
E. Winquist, L. Wood, M. Fenner, K. N. Chi, C. Bokemeyer
Brd. 3B Progression-free survival (PFS) as a new endpoint for designing phase II
trials in patients with refractory germ cell tumors (GCT). (Abstract #4583)
D. R. Feldman, S. Patil, M. J. Trinos, M. Carousso, M. S. Ginsberg, J. Sheinfeld,
D. F. Bajorin, G. J. Bosl, R. J. Motzer
Brd. 3C Impact of delayed orchiectomy (OE) on overall survival (OS) in patients (pts)
with metastatic germ cell tumors (mGCT). (Abstract #4584)
M. Fedyanin, A. Tryakin, D. Kanagavel, E. Burova, T. Zakharova, I. Fainstein,
U. Sergeev, I. Pokataev, A. Garin, S. Tjulandin
Brd. 3D Long term outcome in patients with cisplatin-refractory or multiply relapsed
germ cell tumors following treatment with gemcitabine and oxaliplatin �/�
paclitaxel. (Abstract #4585)
K. Oechsle, C. K. Kollmannsberger, F. Honecker, F. Mayer, C. F. Waller, I. Böhlke,
C. Bokemeyer
Brd. 3E Residual tumor resection in patients with germ cell tumors (GCT): Use of
IGCCCG risk group and tumor volume to predict additional vascular
procedures. (Abstract #4586)
C. Winter, C. Bingoel, R. Witthuhn, P. De Geeter, P. Albers
Brd. 3F Paclitaxel plus BEP (T-BEP) regimen as induction chemotherapy (CT) in
nonseminomatous germ cell tumors (NSGCT) patients with poor prognosis:
A phase II study. (Abstract #4587)
A. Tryakin, M. Fedyanin, U. Sergeev, I. Pokataev, B. Ahmedov, T. Zakharova,
A. Mitin, I. Fainstein, A. Garin, S. Tjulandin
Brd. 3G A phase II study testing the safety and activity of AGS-003 as an
immunotherapeutic in subjects with newly diagnosed advanced stage renal
cell carcinoma (RCC) in combination with sunitinib. (Abstract #4588)
A. Amin, A. Dudek, T. Logan, R. S. Lance, J. M. Holzbeierlein, W. L. Williams,
R. Jain, T. G. Chew, C. A. Nicolette, R. A. Figlin, AGS-003–006 Study Group
Brd. 3H Subgroup analysis and updated results of the randomized study comparing
sorafenib (So) plus interleukin-2 (IL-2) versus So alone as first-line treatment
in metastatic renal cell carcinoma (mRCC). (Abstract #4589)
G. Procopio, E. Verzoni, S. Bracarda, S. Ricci, C. Sacco, L. Ridolfi, C. Porta,
R. Miceli, N. Zilembo, E. Bajetta, on behalf of ITMO Study Group
Brd. 4A A phase II, single-arm study of AS1411 in metastatic renal cell carcinoma
(RCC). (Abstract #4590)
J. E. Rosenberg, H. A. Drabkin, P. Lara Jr., A. L. Harzstark, R. A. Figlin,
G. W. Smith, F. Erlandsson, D. A. Laber
360